INTI
Inhibitor Therapeutics, Inc.Company Information
- Company Name
- Inhibitor Therapeutics, Inc.
- CIK
- CIK0001042418
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- INTI: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- INTI
SEC filing data through
Insider Sentiment
- Last purchase
- 2019-12-12
- Last sale
- 2018-08-30
- Shares purchased (TTM)
- 14,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- —
- Institutional shares owned
- —
- Shares outstanding
- —
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -9.76%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1 | 1 | 2 | 3 | 4 | 4 | 6 | 6 | 7 | 8 | 9 | 10 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Assets Current | 1 | 1 | 2 | 3 | 4 | 4 | 6 | 6 | 7 | 8 | 9 | 10 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Assets | 1 | 1 | 3 | 3 | 4 | 5 | 6 | 6 | 7 | 8 | 9 | 10 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accrued Liabilities Current | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | ||||||
| Long Term Debt And Capital Lease Obligations Current | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Liabilities Current | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | ||||||
| Deferred Revenue Noncurrent | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Long Term Debt And Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Liabilities | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 3 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | ||||||
| Retained Earnings Accumulated Deficit | -57 | -56 | -55 | -54 | -53 | -53 | -52 | -51 | -50 | -49 | -49 | -48 | ||||||
| Stockholders Equity | -3 | -2 | -1 | 0 | 1 | 1 | 2 | 3 | 4 | 5 | 5 | 6 | ||||||
| Liabilities And Stockholders Equity | 1 | 1 | 3 | 3 | 4 | 5 | 6 | 6 | 7 | 8 | 9 | 10 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 174 | 173 | 173 | 173 | 173 | 172 | 172 | 172 | 172 | 172 | 172 | 172 | ||||||
| Shares Outstanding | 174 | 173 | 173 | 173 | 173 | 172 | 172 | 172 | 172 | 172 | 172 | 172 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialInhibitor Therapeutics, Inc. (INTI) — SEC Financial Statements & Analysis
Inhibitor Therapeutics, Inc. (INTI) is a pharmaceutical preparations company, incorporated in DE. Inhibitor Therapeutics, Inc. trades on OTC as: INTI. Inhibitor Therapeutics, Inc. (INTI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Inhibitor Therapeutics, Inc. carries a market cap of $13.86M, a P/E ratio of -4.19x, a P/B ratio of -5.42x, an enterprise value of $13.40M, and an EV/EBITDA multiple of -3.97x. On profitability, it posts a Return on Equity (ROE) of 358.85% and a Return on Assets (ROA) of -145.57%. Per share, it reports EPS of $-0.02, diluted EPS of $-0.02, free cash flow per share of $-0.02, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -4.00% year-over-year and EPS growth of -4.40% year-over-year. On the balance sheet, it maintains a current ratio of 3.36x, a quick ratio of 2.95x, working capital of $411.91K, a debt-to-equity ratio of -1.25x, a debt ratio of 5.02, an interest coverage ratio of -761.43x, free cash flow of $-3.22M (TTM), and net debt of $-467.93K. Figures sourced from SEC EDGAR.
- Market Cap
- $13.86M
- P/E TTM
- -4.19x
- EPS TTM
- $-0.02
- P/B TTM
- -5.42x
- ROE TTM
- 358.85%
- ROA TTM
- -145.57%
- Debt To Equity
- -1.25x
- Free Cash Flow TTM
- $-3.22M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Inhibitor Therapeutics, Inc. in?
Inhibitor Therapeutics, Inc. (INTI) operates in the Pharmaceutical Preparations industry.
What exchange does INTI trade on?
Inhibitor Therapeutics, Inc. (INTI) trades on the OTC.
Where is Inhibitor Therapeutics, Inc. incorporated?
Inhibitor Therapeutics, Inc. is incorporated in DE.
When was Inhibitor Therapeutics, Inc. (INTI)'s most recent SEC filing?
Inhibitor Therapeutics, Inc. (INTI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is INTI's market cap?
Inhibitor Therapeutics, Inc. (INTI) has a market capitalization of $13.86M as of 2026-06-30.
What is INTI's EPS (earnings per share)?
Inhibitor Therapeutics, Inc. (INTI)'s trailing twelve month EPS is $-0.02 as of 2026-06-30.
What is INTI's ROE (return on equity)?
Inhibitor Therapeutics, Inc. (INTI)'s trailing twelve month Return on Equity (ROE) is 358.85% as of 2026-06-30.
What is INTI's ROA (return on assets)?
Inhibitor Therapeutics, Inc. (INTI)'s trailing twelve month Return on Assets (ROA) is -145.57% as of 2026-06-30.
What is INTI's EV/EBITDA?
Inhibitor Therapeutics, Inc. (INTI)'s trailing twelve month EV/EBITDA is -3.97x as of 2026-06-30.